Predictors of Antiviral Therapy in a Post-Transfusion Cohort of Hepatitis C Patients by Maciej Witkos, Qi-Long Yi, Jenny Heathcote, Moira K Kapral, Murray D Krahn

“…INTRODUCTION: In the past, antiviral therapy has been given to 15% to 30% of patients infected with hepatitis C virus (HCV). The efficacy of therapy has recently improved with the addition of ribavirin and pegylated interferon. …”
Get full text

Fasciitis Complicating Subcutaneous Injection of Interferon Beta by Curtis L Cooper, Rachel Gerstein, Kelly Kaita

“…Data pertaining to 65 patients treated at the Health Sciences Center Hepatology Research Unit in Winnipeg, Manitoba describing local complications related to subcutaneous interferon (IFN) injection administered to treat hepatitis C virus infection are presented. Nine patients experienced local erythematous reactions at the injection region. …”
Get full text

Association between Leptin, Metabolic Factors and Liver Histology in Patients with Chronic Hepatitis C by Robert P Myers, Djamila Messous, Thierry Poynard, Francoise Imbert-Bismut

“…BACKGROUND: Steatosis is common in hepatitis C virus (HCV)-infected patients and likely accelerates fibrosis progression. …”
Get full text

TLRs, Alcohol, HCV, and Tumorigenesis by Keigo Machida

“…Ample epidemiological evidence suggests that there is a strong synergism between hepatitis C virus (HCV) and alcoholic liver diseases (ALD). …”
Get full text

Hepatitis B and Hepatitis C Viral Infections in Patients with Chronic Lymphocytic Leukemia by Gerald Y Minuk, Betty Lerner, Spencer B Gibson, James B Johnston, Julia Uhanova, Anton Andonov, Jun Wu

“…BACKGROUND: Whether chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections contribute to the pathogenesis and/or course of chronic lymphocytic leukemia is unclear.…”
Get full text

Viral Response to Specifically Targeted Antiviral Therapy for Hepatitis C and the Implications for Treatment Success by Curtis L Cooper

“…Currently, hepatitis C virus (HCV) antiviral therapy is characterized by long duration, a multitude of side effects, difficult administration and suboptimal success; clearly, alternatives are needed. …”
Get full text

CIHR Canadian HIV Trials Network Co-Infection and Concurrent Diseases Core: Updated Canadian Guidelines for the Treatment of Hepatitis C Infection in HIV-hepatitis C Coinfected Adu... by Mark Hull, Stephen Shafran, Alice Tseng, Pierre Giguère, Marina B Klein, Curtis Cooper

“…BACKGROUND: Hepatitis C virus (HCV) coinfection occurs in 20% to 30% of Canadians living with HIV and is responsible for a heavy burden of morbidity and mortality. …”
Get full text

SEROPREVALENCE OF HEPATITIS C AMONG THE APPARENTLY HEALTHYBLOOD DONORS OF KARACHI by Maeesa Wadood et al

“…Pakistan is among the prevalent countries for hepatitis C virus (HCV). Due to poverty, unemployment, low literacy rate, unawareness and poor health facilities, Pakistani population are susceptible to HCV transmission. …”
Get full text

The Many Difficulties and Subtleties in the Cognitive Assessment of Chronic Hepatitis C Infection by Jefferson Abrantes, Daniel Simplicio Torres, Carlos Eduardo Brandão – Mello

“…Often, patients with hepatitis C virus (HCV) complain of cognitive impairment even before the development of hepatic cirrhosis, which they described as “brain fog.” …”
Get full text

Outcomes of Chronic Hepatitis C Therapy in Patients Treated in Community Versus Academic Centres in Canada: Final Results of APPROACH (A Prospective Study of Peginterferon alfa-2a... by Robert P Myers, Curtis Cooper, Morris Sherman, Richard Lalonde, Helga Witt-Sullivan, Magdy Elkashab, Paul Harris, Rob Balshaw, Christopher Usaty, Paul J Marotta

“…BACKGROUND: In patients chronically infected with the hepatitis C virus (HCV), it is not established whether viral outcomes or health-related quality of life (HRQoL) differ between individuals treated at academic or community centres.…”
Get full text

Antineutrophil Cytoplasmic Antibody Induction due to Infection: A Patient with Infective Endocarditis and Chronic Hepatitis C by Fareed B. Kamar, T. Lee-Ann Hawkins

“…We describe an encounter with a 43-year-old male with chronically untreated hepatitis C virus infection who featured ANCA positivity while hospitalized with acute bacterial endocarditis. …”
Get full text

Failure of Ketoprofen and Interferon Combination Therapy to Improve Interferon-Resistant Chronic Hepatitis C by Frank H Anderson, Lecheng Zeng, Eric M Yoshida, Natalie R Rock

“…Serum aminotransferases (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) and serum hepatitis C virus (HCV) RNA were analyzed before and throughout treatment. …”
Get full text

Single-Dose Infliximab in Hepatitis C Genotype 1 Treatmentnaive Patients with High Serum Levels of Tumour Necrosis Factor-Alpha Does Not Influence the Efficacy of Pegylated Interfe... by Curtis Cooper, Stephen Shafran, Susan Greenbloom, Robert Enns, John Farley, Nir Hilzenrat, Kurt Williams, Magdy Elkashab, Nabil Abadir, Manuela Neuman

“…BACKGROUND: Serum tumour necrosis factor-alpha (TNF-α) levels correlate negatively with hepatitis C virus (HCV) antiviral response.…”
Get full text

Pilot Study of Ofloxacin and Interferon-Alpha Combination Therapy for Chronic Hepatitis C without Sustained Response to Initial Interferon Therapy by Masafumi Komatsu, Tohru Ishii, Tsuyoshi Ono, Takao Hoshino, Tomoyuki Kuramitsu, Takashi Goto, Tomoo Fujii, Itaru Toyoshima, Mitsuro Chiba, Osamu Masamune

“…For the IFN plus OFLX group, OFLX was administered for 12 weeks at a daily dose of 600 mg. Levels of hepatitis C virus RNA declined significantly from the first month after the start of IFN treatment compared with those before administration in both groups. …”
Get full text

The Role of Hepatic Expression of STAT1, SOCS3 and PIAS1 in the Response of Chronic Hepatitis C Patients to Therapy by Sherif El-Saadany, Dina H Ziada, Hanan El Bassat, Wael Farrag, Hesham El-Serogy, Manal Eid, Manal Abdallah, Medhat Ghazy, Hoda A Salem

“…BACKGROUND: The underlying mechanisms of hepatitis C virus (HCV) resistance to treatment are unknown. …”
Get full text

Increased Eligibility for Treatment of Chronic Hepatitis C Infection with Shortened Duration of Therapy: Implications for Access to Care and Elimination Strategies in Canada by Sergio M Borgia, Adenike Rowaiye

“…BACKGROUND: All oral, highly effective direct-acting antiviral combinations, such as sofosbuvir-ledipasvir, have recently been licensed in Canada but cost as much as $67,000 for a 12-week course of therapy, representing a major economic barrier to predominately single-payer health care systems such as that found in Ontario. In hepatitis C virus (HCV) genotype 1 noncirrhotic patients with a baseline viral load of <6×106 IU/mL, treatment with sofosbuvir-ledipasvir can be shortened to eight weeks without compromising ≥95% efficacy. …”
Get full text

Localized Scleroderma Associated with Chronic Hepatitis C by Felipe Ladeira de Oliveira, Luisa Kelmer Côrtes de Barros Silveira, Maria Lourdes Candela Rambaldi, Fabio Cuiabano Barbosa

“…Hepatitis C virus has been associated with various skin conditions, such as porphyria cutanea tarda and lichen planus, as an example. …”
Get full text

High Human Immunodeficiency Virus (HIV) Viral Load and Coinfection with Viral Hepatitis Are Associated with Liver Enzyme Abnormalities among HIV Seropositive Patients on Antiretrov... by Shabani Iddi, Caroline A. Minja, Vitus Silago, Asteria Benjamin, Jastine Mpesha, Shimba Henerico, Benson R. Kidenya, Stephen E. Mshana, Mariam M. Mirambo

“…Hepatitis B virus (HBV) and Hepatitis C virus (HCV) detection and liver enzymes assays (alanine transaminase (ALAT) and aspartate transaminase (ASAT)) were assessed following the standard procedures. …”
Get full text

CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian Guidelines for Management and Treatment of HIV/Hepatitis C Coinfection in Adults by Mark Hull, Marina Klein, Stephen Shafran, Alice Tseng, Pierre Giguère, Pierre Côté, Marc Poliquin, Curtis Cooper, on behalf of The CIHR Canadian HIV Trials Network HIV/Hepatitis C Management and Treatment Guidelines Working Group

“…BACKGROUND: Hepatitis C virus (HCV) coinfection occurs in 20% to 30% of Canadians living with HIV, and is responsible for a heavy burden of morbidity and mortality. …”
Get full text

Recent Advances in Antiviral Therapy for Chronic Hepatitis C by Akihiro Tamori, Masaru Enomoto, Norifumi Kawada

“…Hepatitis C virus (HCV) infection is a major worldwide health problem. …”
Get full text